Authors : Suresh Chandra Mondal, Pinaki Sarkar
DOI : 10.18231/j.ijogr.2021.040
Volume : 8
Issue : 2
Year : 2021
Page No : 188-193
Aim: To determine the efficacy of metformin on clinical profile and metabolic disorders in women with polycystic ovarian syndrome. Polycystic ovarian syndrome, is a heterogeneous endocrinological disorder affecting women of reproductive age and metformin was introduced to influence the pathogenesis.
Materials and Methods: A prospective observational study was conducted on 100 women with polycystic ovarian syndrome, attending department of gynaecology in a tertiary care setting and were divided into two group of 50 each. Metformin was used in 50 patients for one year. Rest 50 patients were advised about diet control and exercise. The parameters like body mass index (BMI), weight, hormonal imbalance, ovulation, and menstrual changes were analysed in both groups. Descriptive statistics for mean, SD were carried and chi-square test was used to test statistical significance using coGuide version V.1.0 and p value set at <0>
Results: The mean age was 25±10 years. Both the groups were comparable with respect to BMI and weight. There was a significant difference between the groups with respect to fasting insulin, which reduced to 7.44±1.12 from 11.97±2 mIU/ml, testosterone levels reduced to 0.59±0.1 from 0.760.3 mIU/ml, luteinizing hormone levels reduced to 8.55±2 from 20.01±7.3 mIU/ml, and LH:FSH ratio reduced to 1.11±0.1 from 2.31±0.2 mIU/ml. In the metformin group, 22 (44%) participants were anovulation before treatment, and ovulation started in 15 (30%) after treatment which was not seen other group.
Conclusion: Clinical, hormonal, and biochemical changes in polycystic ovarian syndrome may effectively be treated by metformin.
Keywords: Hyperplasia, Ovary, Metformin, Obesity, Lifestyle, Insulin.